중심망막정맥폐쇄 환자에서 덱사메타손 유리체강내 삽입물 주입 시 발생한 분절화 1예

A Case of Dexamethasone Intravitreal Implant Fragmentation During the Injection Procedure in Central Retinal Vein Occlusion

Purpose: We report a case of dexamethasone intravitreal implant (Ozurdex?; Allergan, Inc.) fragmentation during the injection procedure in macular edema due to central retinal vein occlusion. Case summary: A 57-year-old man visited our hospital for visual disturbance in his right eye. The patient’s best-corrected visual acuity was 0.02 in the right eye and 1.2 in the left eye. After fundus examination, the patient was diagnosed with central retinal vein occlusion with macular edema, thus bevacizumab was injected in the right eye. However, the macular edema did not improve, and a dexamethasone intravitreal implant was injected in the right eye. Immediately after the dexamethasone intravitreal implant injection, on fundus exam, the drug was observed to be fragmented into 3 pieces without any additional treatment. After 2 months, the patient’s best-corrected visual acuity was 0.4 in the right eye and 1.2 in the left eye. Macular edema decreased according to optical coherence tomography. Conclusions: A case of dexamethasone intravitreal implant fragmentation during an injection procedure has not been previously reported in Korea. Although the drug fragmented, the treatment was effective without complications.